# Generate Biomedicines share price today (Generate Biomedicines, Inc., GENB)

> Generate Biomedicines, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. GENB · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/genb

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $12.57
- Revenue (Jun 2026): $6.3 M (−37.7% on a year ago)
- Profit (Jun 2026), incl. one-off: −$67.3 M (one-off item, see below)
- Operating margin: −1,134.2% (−540.4 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Generate Biomedicines share price today? Generate Biomedicines, Inc.'s share price was $12.57 at the close on 5 November 2026. Since its first close in our records, on 6 March 2026, it has traded between $11 and $17, and at that close it sat 22% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 8 months the share price moved +12% while the S&P 500 moved +9%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Generate Biomedicines pay? Generate Biomedicines, Inc. pays no dividend. In the last 4 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Generate Biomedicines on? Generate Biomedicines is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Generate Biomedicines profitable? Generate Biomedicines, Inc. posted a net loss of $67.3 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $250 M. That loss is 1,065.2% of the quarter's revenue. Read this profit with care: at −$67.3 M it is bigger than the quarter's whole revenue of $6.3 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −1,134.2% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Generate Biomedicines make, and is it growing? Generate Biomedicines, Inc. reported $6.3 M of revenue in the Jun 2026 quarter, −37.7% on the same quarter a year earlier. Over 1 years it has grown 55.9% a year on average. The last full year, FY25, came in at $31.9 M. Recent pace: the last four quarters grew −27.9% on average, against 55.9% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does Generate Biomedicines keep? Generate Biomedicines, Inc.'s operating margin was −1,134.2% in the Jun 2026 quarter, 540.4 percentage points lower than the same quarter a year ago. Across 2 years it has been between −962.6% and −737.0%. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Generate Biomedicines' profit turning into cash? Generate Biomedicines, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $201 M of cash, against −$250 M of profit. After $3.5 M of spending on assets, free cash was −$204 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Generate Biomedicines' cash go? Generate Biomedicines, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $7.0 M on assets over the last 2 years. Averaged over those years that is 10.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $7.0 M over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Generate Biomedicines' P/E ratio, and how does it compare with its own history? Generate Biomedicines, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Generate Biomedicines, Inc. at 50.6× its FY25 revenue of $31.9 M. The P/E comes back here once profit turns positive. ## Is the Generate Biomedicines business getting better or worse? Generate Biomedicines, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Generate Biomedicines earn on its capital? Generate Biomedicines, Inc. earned a ROE of −131% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −782.4% net margin and 0.10× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −782.4% net margin × 0.10× asset turnover × 1.74× leverage (assets divided by equity) ≈ −136.1% on equity. The margin does its share; borrowing is a big part of it. ## Does Generate Biomedicines have too much debt? Generate Biomedicines, Inc. has total debt of $62.6 M against shareholder equity of $456 M as of Jun 2026, so its debt is 0.14× its equity, which is very little. Year by year, that ratio went from 0.22 in FY24 to 0.36 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Generate Biomedicines shareholding pattern? 14.8% of Generate Biomedicines, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Generate Biomedicines from balance-sheet trouble? For Generate Biomedicines, Inc., the Z-score is 6.99. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 6.99 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Generate Biomedicines rank in its industry? There is no score against its industry: Generate Biomedicines, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Generate Biomedicines compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Generate Biomedicines in size? Generate Biomedicines is the 86th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Zenas BioPharma, Inc., Agios Pharmaceuticals, Inc. and Nurix Therapeutics, Inc. Just below it: Novavax, Inc., Absci Corporation and Ultragenyx Pharmaceutical Inc. ### Biotechnology companies close in size

1. [Zenas BioPharma, Inc.](https://www.sectoralpha.in/us/stocks/zbio) $1.7 billion
2. [Agios Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/agio) $1.7 billion
3. [Nurix Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/nrix) $1.6 billion
4. Generate Biomedicines, Inc. $1.6 billion
5. [Novavax, Inc.](https://www.sectoralpha.in/us/stocks/nvax) $1.6 billion
6. [Absci Corporation](https://www.sectoralpha.in/us/stocks/absi) $1.6 billion
7. [Ultragenyx Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/rare) $1.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Himax Technologies, Inc.](https://www.sectoralpha.in/us/stocks/himx) $1.8 billion · Semiconductors
2. [Republic Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/rbcaa) $1.8 billion · Banks - Regional
3. Generate Biomedicines, Inc. $1.8 billion
4. [Global Industrial Company](https://www.sectoralpha.in/us/stocks/gic) $1.8 billion · Industrial Distribution
5. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) $1.8 billion · Medical Instruments & Supplies

## What else do people ask about Generate Biomedicines? ### What is Generate Biomedicines's stock price today? Generate Biomedicines, Inc.'s stock price is $12.57. The whole company is worth $1.6 B on the market. In the last 52 weeks it traded between $11 to $17; today it is 22% of the way up from the low (as of 5 November 2026). ### What were Generate Biomedicines's latest quarterly results? Generate Biomedicines, Inc. reported revenue of $6.3 M and a net loss of $67.3 M for the Jun 2026 quarter. Earnings per share were −$0.52. The operating margin was −1,134.2%, 540.4 percentage points lower than a year earlier (as of 5 November 2026). ### What is Generate Biomedicines's market cap? Generate Biomedicines, Inc.'s market capitalisation is $1.6 B at a stock price of $12.57. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Generate Biomedicines performing? Generate Biomedicines, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Generate Biomedicines's stock price go up? This page does not forecast Generate Biomedicines, Inc.'s stock price. What it shows instead: the stock price is $12.57. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Generate Biomedicines in its business cycle? Generate Biomedicines, Inc.'s FY25 operating margin was −737.0%, against a 2-year range of −962.6% to −737.0%: the middle of its own range, neither a peak nor a low. The latest quarter was −1,134.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Generate Biomedicines story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Generate Biomedicines a stock worth studying right now? What the numbers show: Generate Biomedicines, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.